fbpx
March 9, 2021

Some Medicines and Driving Don’t Mix

Image Español If you’re taking a medication, is it safe to drive? Most likely, yes. Still, the U.S. Food and Drug Administration (FDA) advises you to […]
March 9, 2021

Evelyn Lopez-Brignoni, M.D. – 612542 – 03/02/2021

Delivery Method: VIA UNITED PARCEL SERVICE Product: Drugs Recipient: Evelyn Lopez-Brignoni, M.D. 18320 Franjo RoadPalmetto Bay, FL 33157United States Issuing Office: Center for Drug Evaluation and […]
March 9, 2021

Plasticos Las Palmas, S.A. de C.V – 609475 – 03/01/2021

Delivery Method: VIA UPS Product: Drugs Recipient: Recipient Name Sergio Akira Gonzalez Uyeda Plasticos Las Palmas, S.A. de C.V Vereda de las Violetas 1945640 Tlajomulco de […]
March 9, 2021

Cannafyl – 611957 – 03/01/2021

Product: Drugs Recipient: Recipient Name Mr. Edward Chaney Cannafyl 7595 E. McDonald Dr., Suite 140Scottsdale, AZ 85250United States [email protected] Issuing Office: Center for Drug Evaluation and […]
March 9, 2021

Marco Antonio Rodriguez Fierro – 610110 – 03/01/2021

Delivery Method: VIA UPS Reference #: 320-21-32 Product: Drugs Recipient: Marco Antonio Rodriguez Fierro Avenida Las Americas 409 Col. Leon Xiii67120 Guadalupe, N.L.Mexico Issuing Office: Center […]
March 9, 2021

Gaza Proveedora De Servicios De Hospedaje Y Alimentacion – 611881 – 03/01/2021

Delivery Method: VIA UPS Product: Drugs Recipient: Recipient Name Mr. Luis Armando Garcia Olivares Recipient Title CEO Gaza Proveedora De Servicios De Hospedaje Y Alimentacion Calle […]
March 9, 2021

Supplement to 10/11/1984 letter about policies, procedures and implementation of the Act (Q&A format)

Issued by: Guidance Issuing Office Center for Drug Evaluation and Research This letter provides some information on how FDA intends to implement the Drug Price Competition […]
March 9, 2021

CAMA Wellness Center/IodoRios Company, LLC – 613185 – 03/05/2021

Product: Drugs Recipient: Recipient Name Elise and Max Rivers CAMA Wellness Center/IodoRios Company, LLC 6782 Germantown Ave.Philadelphia, PA 19119United States [email protected] Date:               March 5, 2021 […]
March 8, 2021

Seventh of a series of letters about the Act providing guidance on the “130-day exclusivity” provision of section 505(j)(4)(B)(iv) of the FD&C

Issued by: Guidance Issuing Office Center for Drug Evaluation and Research The FDA published Good Guidance Practices in February 1997. This guidance was developed and issued […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0